Diskusjon Triggere Porteføljer Aksjonærlister

Targovax (TRVX) Småprat

16,55 i snittpris her. :smile:

Hun øker kursmålet til 15 :smile:

Med TG01 grovt priset til +/- 0 nok så burde dette være en nobrainer fremover.

3 Likes

Blir spennende å se fremover om dette var gnisten man trengte. Drømmer om høyt 20-tall i nær fremtid

1 Like

Neste er interim mesothelioma, også innen utgangen juni?

Kan ikke se så mye annet som kan gjøre ting noe bedre, det må isåfall være oppkjøp/partner eller accelerated approval FDA ? Det er iallefall megabull i forhold

Blir jo spennende å se frem mot ASCO også. Det er vel snakk om noe interim-data i h12018 også for ONCOS-biten

OS cohort II = Still counting.

Omsetning til nå 9 mill. En tilsvarende melding fra BGBIO eller NANO og man hadde rundet 90 mill 20 min seinere…

OB, why you so olje og laks??? :skull:

Ja jeg tenkt på TG plattformen. Det var jo det beste man neste kunne håpet på.

ONCOS biten er jo bare en lekker dessert. Men denne har jo bein å stå på allerede. TG har jo vært bortføyd.

Og ja, tenker det samme. Hva var det som sendte BBIO og PCIB opp tidligere, hvilke meldinger var det? Jeg har ikke fulgt disse så tett

1 Like

Dette går mot AA (Accelerated Approval) Bukspyttkjertel pasienter har ikke hatt forbedret produkt på 45 år. - focuss

2 Likes

:joy::joy::joy:

3 Likes

Ikke mine heller!

Alldeles ikke mine heller nei :slight_smile:

Nå skal det bli morro og høre på Jadeberg til neste uke på podcasten altså !

6 Likes

Tipper det blir nye 16 prosent i morgen :money_mouth_face:
Noen andre som vil tippe?

20% imorgen, alle som ikke fikk med seg hva som skjedde i dag :wink::cowboy_hat_face:

Tok et 100k lodd. :sunglasses:

1 Like

100k aksjer eller 100 kilokroner?

Jeg tipper ikke kurs , for Oslo børs forstår vist ikke targovax :stuck_out_tongue_winking_eye:

Sier bare en ting : LES børsmeldingen nøye , det er så mye positivt der :ok_hand:t4:

5 Likes

SOTIO starts Phase I/II trial of DCVAC in combination with ONCOS-102: the Targovax adenovirus based immunotherapy

May 24, 2018
Source: Press Release

SOTIO, a biotechnology company owned by the PPF Group, announces today that the first patient was enrolled to the SP015 clinical trial of a combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming engineered human serotype 5 adenovirus, for patients with prostate cancer. The trial is planned for the United Kingdom and the Czech Republic. SOTIO is collaborating with Targovax,a clinical stage immuno-oncology company developing ONCOS-102.

The first patient has been enrolled in the clinical trial SP015 by the principal investigator Dr. Ladislav Jarolím at Motol University Hospital (Prague, Czech Republic). Patients’ recruitment is planned also in the UK. It is the first time that a clinical trial combining cellular immunotherapy based on dendritic cells with an oncolytic virus therapy is realized by a biotechnology company in the region of Central and Eastern Europe (CEE).

SP015 (Eudra CT: 2015-004314-15) is a Phase I/II, single-arm clinical trial to evaluate the safety and immune activation of the combination of DCVAC/PCa, an active cellular immunotherapy, and ONCOS-102, an immune-priming adenovirus, in men with advanced metastatic castration-resistant prostate cancer. In total up to 15 patients are planned to be enrolled into the trial. The trial builds on the hypothesis that ONCOS-102 may enhance the anti-tumor immune responses generated by dendritic cells loaded with tumor antigens and thus help the immune system to overcome evasion strategies employed by tumors.

Radek Spisek, CEO of SOTIO, said: “By combining an autologous active cellular therapy with an oncolytic virus, we had to overcome various regulatory and operational challenges. We are very happy to have succeeded in initiating such a complex trial, the first of its kind ever conducted in the Czech Republic and the CEE region. The SP015 clinical trial will help us to gather critical evidence necessary to develop innovative immunotherapies for the treatment of a cancer that threatens 1 in 5 men globally.”

Ludek Sojka, Chief Operating Officer of SOTIO, said: “SP015 will examine the safety and efficacy of combining our active cellular immunotherapy with a promising adenovirus-based product. We believe the results of this study will move us closer to developing new therapy combinations that produce synergistic effects and bring clear benefits to patients. The use of an oncolytic virus in the treatment of cancer was previously successfully tested in different cancer indications and we hope to broaden the portfolio of indications in future.”

About DCVAC/PCa:

DCVAC/PCa was the first SOTIO product to enter clinical research. SOTIO DCVAC/PCa is an active cellular immunotherapy treatment for prostate cancer patients; DCVAC/PCa is produced individually for each patient using the patient’s own dendritic cells (that are part of the immune system), to induce an immune reaction against tumor antigens. SOTIO has been sponsoring five Phase II clinical trials and one global Phase III (VIABLE) clinical trial in patients with prostate cancer. Other Phase II and Phase I/II clinical trials with products using the same dendritic cells based platform (DCVAC) are conducted in ovarian cancer and lung cancer indications.

About Targovax and ONCOS-102:

Targovax is a clinical stage company focused on developing and commercializing novel immuno-oncology therapies to target, primarily, treatment-resistant solid tumors. The company’s development pipeline is based on two novel proprietary platforms. The first platform, ONCOS, uses oncolytic viruses as potential multi-target, neo-antigen therapeutic cancer vaccines. ONCOS uses an adenovirus that has been engineered to be an immune activator that selectively targets cancer cells. The second platform, TG, are neo-antigen cancer vaccines designed to specifically treat tumors that express mutated forms of the RAS protein. The Targovax development pipeline has three novel therapeutic candidates in clinical development covering six indications.

ONCOS-102 is the lead adenovirus-based pipeline product of Targovax – a purposefully engineered human serotype 5 adenovirus optimized to induce systemic anti-tumor T cell responses in cancer patients. Targovax has completed a Phase I clinical study with this product and continues to test it in further combination clinical trials in several solid tumor indications.

BACK TO LIST
http://www.sotio.com/news-publications/news/sotio-starts-phase-i-ii-trial-of-dcvac-in-combination-with-oncos-102-the-targovax-adenovirus-based-immunotherapy

8 Likes

1 av de 2 ja :grinning: